Music Therapy for Major Depressive Disorder Residual Symptoms
NCT ID: NCT02925325
Last Updated: 2016-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
48 participants
INTERVENTIONAL
2016-10-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treating Major Depressive Disorder With Music and Low-frequency Rhythmic Sensory Stimulation
NCT02685982
Treatment Resistant Depression in America Latina
NCT03207282
Comparing Various Treatments for Achieving and Maintaining Remission of Depression
NCT00227955
Rhythm and Depression
NCT02857036
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
NCT07166289
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To evaluate the clinical changes related to the application of music therapy as a treatment for Residual Symptoms of Depression.
SPECIFIC OBJECTIVES:
1. Compare the pre and post treatment of residual symptoms by the HAM-D-21, BDI, SCL-90-R and CIDRS levels.
2. Compare the change of pre and post treatment obtained by the instruments for quality of life (WHOQOL-BREF), functioning (GAF and PSP) and perceived stress (PSS) values.
METHOD
Design - A randomized controlled trial with two treatment arms: the experimental group Music Therapy (MT); and control group Usual (TU) treatment. MT treatment group will design and will be completed in a period of two months, with an outline of 8 sessions (one per week). The TU corresponds to the usual clinical psychiatric treatment (drug) assigned by the attending physician in the INPRF.
POPULATION - patients attending the outpatient department of the National Institute of Psychiatry "Ramon de la Fuente" between 20 and 45, considered in remission of major depressive disorder (MDD) (DSM-IV) score ≤7 be included points on the Hamilton Depression Scale of (HAM-D-21) and / or ≤9 points in the Beck Depression Inventory (BDI), which have had a positive response to drug treatment and / or remain with pharmacotherapy phase continuation or maintenance, and there report or detection of persistent residual symptoms.
In this research, both participants in the control group and the experimental group, remain drug therapy throughout the study according to the instructions of the attending physician, so the period and type of administration shall be the sole decision of the same. In any case this protocol assessments will be conducted as planned. In the case of any change in drug therapy researchers take note of it for consideration in the final results.
SAMPLE SIZE - According to calculations made, the sample size is 48 patients. With an allocation of 24 patients in each treatment (MT and UT). It is considered to recruit an approximate previous historical studies in SRD sample (Fava et al., 1996; Fava et al., 1998).
To calculate the sample size formula for "comparison of two proportions" (Fernández, 2001), which was used as follows:
Where:
n = subjects required in each of the samples
Za = Z value corresponding to the desired risk
Zb = Z value corresponding to the desired risk
p1 = Value of the proportion in the control group, placebo control or usual treatment.
p2 = Value of the proportion in the group of the new treatment, intervention or technique.
p = average of the two proportions p1 and p2
The following data were considered:
* a confidence level of 95% or safety was established.
* A power of 80%.
* the effectiveness of standard treatment in preventing relapse (Fava et al was set at 32%., 1996; Paykel et al., 1999; Fava et al., 1998; Teasdale et al., 2000; Ma \& Teasdale, 2004).
* was set at 70% of the desired effectiveness for MT in preventing relapse, considering the performance of psychotherapies reported (Fava et al., 1996; Paykel et al., 1999; Fava et al., 1998; Teasdale et al, 2000; Ma. \& Teasdale, 2004).
This accounted for 15% of subjects the possible loss of the sample according to the following formula:
Losses set to n = (1/1-R) shows
n = number of subjects lossless
R = expected loss ratio
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Music Therapy
Music therapy 8 weekly sessions
Music therapy
Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
Usual Treatment
It is the usual medical treatment.
Usual Treatment
It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Music therapy
Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
Usual Treatment
It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or Female Patients.
* Age 20-45 years.
* Previous diagnosis of MDD according to DSM-IV.
* Presence of residual symptoms, with a score of ≤7 points in the HAM-D-21 and / or ≤9 points in BDI.
* Patients who agree to sign informed consent sheet.
* Patients without a psychotherapeutic treatment during the 8 weeks prior to baseline.
* Patients with any pharmacological antidepressant treatment in continuation phase or maintenance (Eg. SSRIs, benzodiazepines) with good adherence.
Exclusion Criteria
* Patients with suicidal risk.
* Patients with comorbid Axis I.
* Patients with comorbid Axis II as the primary diagnosis.
* Patients with any type of hearing chronic medical illness, neurological or (Eg. Hearing loss, tinnitus, etc.)
* Patients with addiction to any substance (except caffeine and nicotine).
* Patients with medical or psychological problems related to music (Eg. Amusia or musicogenic Epilepsy.
* Pregnant women.
20 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jorge J. González Olvera
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Enrique O Flores Gutierrez, MD PhD
Role: STUDY_CHAIR
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Jorge Julio González Olvera, MD PHD
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Nacional de Psiquiatria Ramon de la Fuente Muñiz
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INPRF_MUS_THER_MDD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.